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ABSTRACT 
Purpose Some macrolide and quinolone antibiotics (MQAB) are associated with QT-
prolongation and life-threatening torsade de pointes arrhythmia (TdP). MQAB may 
also inhibit cytochrome P450 isoenzymes and thereby cause pharmacokinetic drug-
drug interactions (DDI). There is limited data on the frequency and management of 
such risks in clinical practice. This study aimed to quantify co-administration of 
MQAB with potentially interacting drugs and associated adverse drug reactions. 
Methods We conducted an observational study within our pharmacoepidemiological 
database derived from electronic medical records of a tertiary care hospital. Among 
all users of MQAB associated with TdP we determined the prevalence of additional 
QT-prolonging drugs and risk factors for TdP, and identified contraindicated co-
administrations of simvastatin, atorvastatin or tizanidine. ECG-monitoring and 
associated adverse drug reactions were validated in medical records. 
Results Among 3444 administered courses of clarithromycin, erythromycin, 
azithromycin, ciprofloxacin, levofloxacin or moxifloxacin there were 1332 (38.7 %) 
with concomitant use of additional QT-prolonging drugs. Among those we identified 7 
adverse drug reactions related to QT-prolongation, but 49.1 % had no ECG-
monitoring. Of all MQAB users 547 (15.9 %) had hypokalemia. Forty-four MQAB 
users had contraindicated co-administrations of simvastatin, atorvastatin or 
tizanidine, and 3 of those related adverse drug reactions. 
Conclusion In the studied real-life setting we found a considerable number of MQAB 
users with additional risk factors for TdP but no ECG monitoring. However, adverse 
drug reactions were rarely found, and costs vs. benefits of ECG monitoring have to 
be weighted. In contrast, avoidable risk factors and selected contraindicated 
pharmacokinetic interactions are clear targets for implementation as automated 
alerts in electronic prescribing systems. 
  
INTRODUCTION 
Macrolide and quinolone antibiotics (MQAB) are among the most frequently 
prescribed drugs that are associated with life-threatening torsade de pointes (TdP) 
cardiac arrhythmia [1-5]. Information on the assessment of their potential risk to 
cause TdP vs. therapeutic benefits are featured in their Summary of Product 
Characteristics (SPC) and other resources such as guidelines, websites and clinical 
decision support software [6, 7]. Patients’ resilience to drug-induced TdP is often 
described as ‘repolarization reserve’, referring to the ventricle’s capacity to 
compensate delayed repolarization [8]. Prolongation of the QT-interval is an 
important predictor of TdP, and ECG monitoring is therefore indicated in patients 
exposed to QT-prolonging drugs with a high risk of TdP. The risk is partially dose-
dependent and highest in patients with concomitant administration of several QT-
prolonging drugs. Indeed, in clinical practice patients with drug-associated TdP had 
typically been exposed to several risk drugs. TdP is also associated with additional 
factors including high age, female sex, hypokalemia, heart diseases and renal 
impairment [9-11]. If the QTc interval exceeds 500 ms or there is a drug-associated 
increase by more than 60 ms, QT-prolonging drugs should usually be discontinued 
[12]. However the risk of TdP may already be increased at QTc intervals above the 
upper limit of normal, which is commonly defined as 450 ms for men and 460 ms for 
women [13]. Inpatients of a tertiary care hospital may frequently feature reduced 
repolarization reserves due to polypharmacy and other risk factors for TdP. 
Therefore, awareness of TdP-inducing drugs and careful ECG monitoring are 
important parts of proactive drug safety management in this population [14]. 
Furthermore, some MQAB are also well known for avoidable pharmacokinetic DDI 
[15, 16]. Clarithromycin, erythromycin and ciprofloxacin are strong inhibitors of 
cytochrome P450 isoenzymes (CYP). Their co-administration with certain substrates 
may outweigh any potential benefits, especially if ‘victim-drugs’ are prescribed in high 
doses and if therapeutic alternatives are available. The latency time of resulting 
adverse drug reactions (ADR) has a broad range. DDI with MQAB may lead to 
simvastatin-induced rhabdomyolysis only after several weeks of co-administration 
[17-19], whereas ciprofloxacin may cause a 7- to 10-fold increase of tizanidine cmax 
and AUC within 24 hours and result in severe hypotension and reduced psychomotor 
functions [20]. 
The present study aimed to quantify co-administration of MQAB with QT-prolonging 
and other potentially interacting drugs, relevant risk factors and the frequency of 
associated adverse drug reactions in the real-life setting of hospitalized patients. 
 
 
METHODS 
Data Source 
The study was conducted using data from the calendar year 2012 of our previously 
described comprehensive pharmacoepidemiological hospital database [21]. The 
database contains information on electronic drug prescriptions, demographics, 
laboratory results and diagnoses for hospitalized patients of a Swiss tertiary care 
hospital. For the assessment of ECG monitoring and outcome validation of potential 
DDI we reviewed original electronic medical records unless patients had refused 
consent to use their data for research upon admission. 
 
Study design 
Selection of the study population and overall study design are presented in Figure 1. 
We conducted a retrospective observational study that analyzed usage patterns, 
ECG monitoring, potential DDI, laboratory data and relevant comorbidities in MQAB 
users of a tertiary care hospital. The cantonal ethics committee, the hospital’s 
medical director and the hospital’s center for clinical research had approved the data 
extraction, the setup and analysis of our anonymized pharmacoepidemiological 
database, and the access to original medical records for our research studies. 
 Usage patterns of QT-prolonging MQAB, co-administration of potentially interacting 
drugs and risk-factors for TdP 
For the present study we developed, programmed and validated algorithms that 
searched our database for patients, patient-days and hospitalizations with exposure 
to MQAB and co-administered drugs of interest. Few hospitalizations with 
administration of two or more of the studied MQAB contributed to more than one 
exposure group and were accordingly counted more than once. We analyzed the 
following MQAB based on their established high potential to cause TdP according to 
information from their SPC and additional scientific resources [7, 22-25]: 
ciprofloxacin, clarithromycin, erythromycin, azithromycin, levofloxacin and 
moxifloxacin. For all users of those MQAB we identified additional co-administered 
drugs that also have an established high risk for QT-prolongation and TdP. 
Furthermore we identified selected drugs with well-documented relevant CYP-
mediated pharmacokinetic interactions with the respective MQAB, i.e. concomitant 
administration of clarithromycin or erythromycin with simvastatin or high-dose 
atorvastatin (≥ 40 mg/d), and combined use of ciprofloxacin with tizanidine. 
Further algorithms identified additional risk factors for TdP. Current hypokalemia 
below 3.3 mmol/l or renal impairment with a decreased eGFR [26] that requires 
dose-reduction for clarithromycin, erythromycin, ciprofloxacin and levofloxacin. For 
patients with renal impairment we evaluated whether recommended dose-
adjustments of the respective MQAB had actually been made [7]. Furthermore, we 
identified relevant cardiac comorbidities that may increase the risk of TdP based on 
documented ICD-10 codes of the following heart diseases: heart failure, 
cardiomyopathy, angina pectoris, myocardial infarction, heart murmurs, aortic 
stenosis, coronary artery stenosis, cardiac failure, QT prolongation, pacemaker 
implantation, ventricular septum defect, coronary interventions, palpitations, atrial 
fibrillation or flutter, supraventricular arrhythmia, tachycardia, and tachy-bradycardia 
[3]. 
 
ECG-monitoring and evaluation of adverse events associated with potential 
medication errors 
We assessed monitoring for QT-prolongation by reviewing all documented ECGs in 
patients’ original medical records performed up to one week before (baseline) or 
during the co-administration of potentially interacting drugs for each hospitalization. 
A corrected QT interval (QTc) of >450 ms in men and >460 ms in women is 
associated with increased cardiovascular mortality and defined as the upper limit of 
normal by the American Heart Association. Longer QTc-intervals were accordingly 
categorized as ‘abnormal QTc’ for the present study [13, 27]. A QTc-interval above 
500 ms significantly increases the risk of TdP and sudden cardiac death, and was 
defined as ‘long QTc’ [12]. For patients with abnormal and long QTc-intervals we 
reviewed the original ECG and comprehensive medical records for other, not drug-
related contributing QTc-prolonging factors such as pacemakers, left bundle branch 
blocks or presence of tachycardia (heart rate >100/min). Only if no such confounders 
were identified, we assessed the causal relationship with the respective QT-
prolonging drugs according to standardized WHO/CIOMS causality assessment 
criteria [28]. 
For the studied pharmacokinetic DDI involving simvastatin and atorvastatin we 
identified symptoms, signs and diagnoses of myopathy in comprehensive medical 
records including laboratory results of creatine kinase (CK) measurements [7]. For 
interactions involving tizanidine we evaluated any documentation of hypotension, 
drowsiness and reduced psychomotor functions [7]. 
 
Data analysis 
Data analysis was descriptive with presentation of results in tables as appropriate. 
Frequencies were calculated with regard to individual patients, hospitalizations and 
patient-days. Data management and analyses were performed with STATA Version 
13.1 (STATA Corporation, College Station, TX, USA). 
 
 
RESULTS 
Characteristics of the study population 
Among 29969 patients from our database that had been hospitalized in 2012, 9777 
(32.6%) had received treatment with systemic antibiotics. Amoxicillin-clavulanic acid 
was by far the most frequently used antibiotic (n=4112, 42.1%), and 29.1% of 
patients with systemic antibiotic treatment had received MQAB associated with TdP. 
Characteristics of the studied MQAB users and frequency distribution of different 
MQAB are presented in Table 1. Ciprofloxacin was the second most frequently used 
antibiotic in the hospital (19.2% of all patients with systemic antibiotic treatment) and 
by far the most frequently used MQAB. Mean and median duration of hospitalization 
for MQAB users were 19.2 and 5 days. 
 
Co-medication of MQAB with additional QT-prolonging drugs, other risk factors for 
TdP and dose-adjustment in renal impairment 
Co-medication of MQAB with other QT-prolonging drugs and prevalence of additional 
risk factors for TdP are presented in Table 2. Among 3444 courses of administered 
MQAB, additional drugs known to cause TdP were administered in 1332 (38.7 %). In 
14.2% even two or more additional QT-prolonging drugs were administered. Some 
patients received up to 6 drugs known to cause TdP on the same day, frequently 
involving antiemetics, azole-antifungals and antidepressants. Patients using 
clarithromycin, azithromycin, levofloxacin or moxifloxacin were more frequently 
exposed to at least one additional drug known to cause TdP (between 51.5 and 60.4 
%) than patients receiving erythromycin (29.9%) or ciprofloxacin (30.3 %). Current 
hypokalemia below 3.3 mmol/l, an important risk factor for TdP, was documented in 
15.9%. For users of clarithromycin, erythromycin, ciprofloxacin and levofloxacin lack 
of recommended dose reduction of MQAB in the presence of impaired renal function 
was found in 122 (3.8 %) of administered courses. These occurred in 91 
hospitalizations with ciprofloxacin (daily doses of >500 mg while eGFR <30ml/min or 
>1000 mg while eGFR 30-60 ml/min), in 16 hospitalizations with clarithromycin (daily 
doses of >500 mg while eGFR <30 ml/min), and in 15 hospitalizations with 
levofloxacin (daily doses of >250 mg while eGFR <20 ml/min or >500 mg while eGFR 
20-50 ml/min). Approximately one in three patients exposed to the studied MQAB 
had a documented ICD-10 diagnosis of heart diseases associated with an increased 
risk for TdP. 
 
ECG-monitoring in patients at risk for TdP 
For 1332 administered MQAB courses with at least one additional QT-prolonging 
drug, medical records including performed ECGs could be further reviewed for 1236 
(92.8%). Frequencies of ECG-monitoring and further risk factors for TdP in those 
patients are presented in Table 3. In 50.9 % adequate ECG monitoring was 
documented. Among hospitalizations with adequate ECG monitoring and abnormal 
QTc (n= 55), patients with non-drug causes for ECG abnormalities (n= 30), or 
patients with an ECG performed before exposure to the DDI (n= 12) were excluded 
from the CIOMS causality assessment. Thereafter 13 individual patients with an 
abnormal / long QTc interval remained for formal causality assessment. For 7 
patients with QTc between 478 and 518 ms causality of the involved drugs known to 
prolong QT interval and cause TdP interval was classified as ‘possible’, and further 
details are presented in Table 4. We identified no episodes of TdP. 
 
Pharmacokinetic interactions of MQAB with simvastatin, atorvastatin and tizanidine 
Among the 546 individual patients taking clarithromycin or erythromycin we detected 
9 patients with co-administration of simvastatin, 6 thereof taking 40 - 80 mg daily. An 
additional 22 patients were exposed to concomitant use of ≥40 mg atorvastatin daily. 
In none of these patients symptoms or signs of myopathy including elevated creatine 
kinase measurements indicated causally related adverse drug reactions. 
Among the 2247 administered courses of ciprofloxacin we detected 13 with 
concomitant exposure to tizanidine, 5 thereof with ≥6mg/d. Three patients 
experienced episodes of hypotension shortly after this combination was 
administered, and 2 patients were treated with cardiac stimulants (etilefrine and 
midodrin), but without cessation of tizanidine-ciprofloxacin co-administration (Table 
4). Causality for the decreases in blood pressure assessment in relation to the DDI 
was assessed as ‘possible’ in all three cases. 
 
 
DISCUSSION 
This study describes the use, co-medication and risk management of MQAB in the 
real-life setting of a tertiary care hospital with regard to TdP and to selected clinically 
relevant pharmacokinetic DDI. With the exception of ciprofloxacin, the studied 
potentially QT-prolonging MQAB were only used in a small proportion of patients. 
And ciprofloxacin is generally considered ‘less torsadogenic’ than other quinolones 
and was only recently added to the list of drugs with a known risk for TdP [2, 29, 30]. 
At the same time, it is remarkable how many MQAB users had additional risk factors 
for TdP. Most notably, more than one third were exposed to additional QT-prolonging 
drugs, and about one in six MQAB users also had hypokalemia, a risk factor that is 
usually easy to correct in hospitalized patients [12, 31]. Indeed, the SPC of 
clarithromycin features hypokalemia as an explicit contraindication to its use [7, 32], 
yet we detected 361 patient-days in which clarithromycin was administered despite 
current serum potassium below 3.3 mmol/l, representing 8.5 % of all patient-days 
with exposure to clarithromycin. Renal impairment is another important risk factor for 
TdP, which may be explained by the reduced renal elimination of many drugs known 
to cause TdP and an increased risk for electrolyte disturbances [12]. We identified 
lack of dose-adjustment for renally eliminated MQAB. Although this concerned only a 
little less than 5% of MQAB users it represents a risk that can be avoided if 
physicians are aware of it at the time of prescription. 
ECGs for the monitoring of abnormal or long QT intervals were available in about 
50% in MQAB users with additional QT-prolonging co-medication. The higher 
proportion of patients with diagnosed heart diseases among the patients with 
adequate ECG monitoring may most likely be explained by confounding from the 
cardiac disease itself rather than a higher awareness for the drug-induced risk of 
TdP. A high proportion of patients without adequate ECG monitoring had at least one 
additional risk factors for TdP, and it is likely that additional cases of abnormal / long 
ECG remained undetected. On the other hand, medical records were searched for 
adverse drug reactions also in patients without ECG-monitoring, and overall only 7 
cases of prolonged QTc between 478 and 518 ms were identified, and no case of 
TdP. The resources required for more intense and guideline-compliant ECG-
monitoring must therefore be weighted against expected benefits. Some US tertiary 
care hospitals have successfully developed and introduced automated algorithms 
with subsequent alerts for ECG with QTc of >500 ms [33-36]. However, in order for 
such a system to be effective, a current plus a recent pre-treatment ECG are 
needed, and also pre-treatment ECGs must be justified [37, 38]. Our findings 
suggest that automated algorithms to improve the risk-assessment may include the 
following modifiable risk factors: hypokalemia, lack of dose adaptation to renal 
insufficiency, and ideally also suggestions for alternative co-medication. 
Nevertheless, the development of cost-effective ECG-monitoring algorithms and their 
implementation remains challenging, for MQAB users as well as for other high risk 
groups such as users of psychiatric drugs [39]. 
In comparison to QT-prolonging combinations, management implications of our 
findings regarding selected contraindicated combinations of MQAB with known 
pharmacokinetic interactions are straightforward. A high proportion of patients with 
such combinations had associated adverse drug reactions, and review of individual 
situations in original medical record showed that these combinations could have 
been avoided, as there would have been alternative management options in all 
cases. Rather simple automated simple alert-algorithms would therefore be an 
efficient preventive measure with a favorable relation of costs vs. benefits. 
 
In conclusion our study found a considerable number of MQAB users with additional 
QT-prolonging co-medication and other risk factors for TdP in hospitalized patients, 
and a high proportion of those had no ECG monitoring. However, adverse drug 
reactions were rarely found, and benefits of intense ECG monitoring as well as 
benefits of QT-prolonging co-medication in MQAB users have to be weighted against 
costs. In contrast, correctable co-factors in MQAB users such as hypokalemia, lack 
of dose-adjustment in renal impairment and selected contraindicated 
pharmacokinetic interactions are clear targets for implementation as preventive 
automated alerts in electronic prescribing systems.   
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Table 1: Characteristics of the study population 
 
 Hospitalizations 
  n (%) 
All analyzed MQAB users 3240 (100) 
   
Sex   
Male 1913 (59.0) 
Female 1327 (41.0) 
   
Age distribution   
<18 14 (0.4) 
18-44 694 (21.4) 
45-64 1195 (36.9) 
65-84 1205 (37.2) 
≥85 132 (4.1) 
   
Use of studied antibiotics   
Macrolides   
Clarithromycin 476 (14.7) 
Erythromycin 184 (5.7) 
Azithromycin 113 (3.5) 
Quinolones   
Ciprofloxacin 2247 (69.4) 
Levofloxacin 321 (9.9) 
Moxifloxacin 103 (3.2) 
   
Units with highest use of MQAB   
Urology 677 (20.9) 
Viszeral- and transplantation surgery 386 (11.9) 
Internal medicine 381 (11.8) 
Pneumology 271 (8.4) 
Haematology 170 (5.2) 
   
Most frequent primary ICD-10 diagnoses for hospitalizations with MQAB use   
Malignant neoplasms of lymphoid, hematopoietic and related tissue C81-C96 177 (5.5) 
Complications of surgical and medical care, not elsewhere classified T80-T88 151 (4.7) 
Other diseases of the urinary system N30-N39 142 (4.4) 
Influenza and pneumonia J09-J18 139 (4.3) 
Malignant neoplasms of digestive organs C15-C26 127 (3.9) 
 
 
Table 2: Prevalences of QT-prolonging comedication and other risk factors for TdP in MQBA users 
 
 
Clarithromycin  Erythromycin  Azithromycin  Ciprofloxacin  Levofloxacin  Moxifloxacin 
  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days  Hospitalizations Patient-days 
  n % n %  n % n %  n % n %  n % n %  n % n %  n % n    % 
Use of antibiotic 476 (100) 4238 (100)  184 (100) 901 (100)  113 (100) 725 (100)  2247 (100) 12989 (100)  321 (100) 2389 (100)  103 (100) 857 (100) 
  
   
   
   
   
   
   
   
   
   
   
   
  
Co-medication with at least 
one QT-prolonging drug 282 (59.2) 3163 (74.6) 
 
55 (29.9) 223 (24.0) 
 
67 (59.3) 561 (77.4) 
 
681 (30.3) 3923 (30.2) 
 
194 (60.4) 1165 (48.8) 
 
53 (51.5) 570 (66.5) 
Co-medication with two or 
more QT-prolonging drugs 166 (34.9) 2541 (60.0) 
 
27 (14.7) 72 (8.0) 
 
37 (32.7) 243 (33.5) 
 
174 (7.7) 1271 (9.8) 
 
58 (18.1) 198 (8.3) 
 
28 (27.2) 256 (29.9) 
  
   
   
   
   
   
   
   
   
   
   
   
  
Most frequently used QT-
prolonging co-medication 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
  Escitalopram 17 (3.6) 345 (8.1)  2 (1.1) 9 (1.0)  5 (4.4) 25 (3.4)  75 (3.3) 395 (3.0)  6 (1.9) 43 (1.8)  2 (1.9) 24 (2.8) 
  Fluconazole 17 (3.6) 30 (0.7)  10 (5.4) 23 (2.6)  0 (0.0) 0 (0.0)  72 (3.2) 311 (2.4)  33 (10.3) 93 (3.9)  6 (5.8) 14 (1.6) 
  Ondansetron 28 (5.9) 99 (2.3)  23 (12.5) 61 (6.8)  13 (11.5) 62 (8.6)  221 (9.8) 489 (3.8)  119 (37.1) 687 (28.8)  5 (4.9) 24 (2.8) 
  Domperidone 185 (38.9) 2446 (57.7)  22 (12.0) 87 (9.7)  56 (49.6) 495 (68.3)  269 (12.0) 2192 (16.9)  63 (19.6) 324 (13.6)  32 (31.1) 347 (40.5) 
  Clarithromycin - - - -  1 (0.5) 1 (0.1)  3 (2.7) 3 (0.4)  43 (1.9) 759 (5.8)  11 (3.4) 37 (1.5)  23 (22.3) 323 (37.7) 
  Azithromycin 3 (0.6) 3 (0.1)  1 (0.5) 1 (0.1)  - - - -  18 (0.8) 137 (1.1)  2 (0.6) 6 (0.3)  6 (5.8) 47 (5.5) 
  Itraconazole 131 (27.5) 2460 (58.0)  2 (1.1) 2 (0.2)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 
  Ciprofloxacin 43 (9.0) 759 (17.9) 
 
14 (7.6) 45 (5.0)  18 (15.9) 137 (18.9)  - - - -  13 (4.0) 18 (0.8)  3 (2.9) 3 (0.4) 
  Erythromycin 1 (0.2) 1 (< 0.1)  - - - -  1 (0.9) 1 (0.1)  14 (0.6) 45 (0.3)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 
  Mirtazapine 20 (4.2) 131 (3.1)  7 (3.8) 35 (3.9)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 
  Levofloxacin 11 (2.3) 37 (0.9)  0 (0.0) 0 (0.0)  2 (1.8) 6 (0.8)  13 (0.6) 18 (0.1  - - - -  0 (0.0) 0 (0.0) 
  Moxifloxacin 23 (4.8) 323 (7.6)  0 (0.0) 0 (0.0)  6 (5.3) 47 (6.5)  3 (0.1) 3 (0.0)  0 (0.0) 0 (0.0)  - - - - 
  
   
   
   
   
   
   
   
   
   
   
   
  
Hypokalemia (<3.3 mmol/l)1 110 (23.1) 361 8.5)  16 (8.7) 37 (4.1)  18 (15.9) 36 (5.0)  321 (14.3) 982 (7.6)  58 (18.1) 136 (5.7)  24 (23.3) 61 (7.1) 
  
   
   
   
   
   
   
   
   
   
   
   
  
Renal impairment with need 
for MQAB dose reduction2 87 (18.3) 724 17.1) 
 
2 (1.1 2 (0.2) 
 
- - - - 
 
660 (29.4) 3723 (28.7) 
 
67 (20.9) 347 (14.5) 
 
- - - - 
    without recommended  
        dose-reduction 16 (3.4) 29 (0.7) 
 
0 (0.0) 0 - 
 
- - - - 
 
91 (4.0) 236 (1.8) 
 
15 (4.7) 54 (2.3) 
 
- - - - 
  
   
   
   
   
   
   
   
   
   
   
   
  
ICD-10 diagnosis associated 
with elevated TdP risk 232 (48.7) - - 
 
24 (13.0) - - 
 
40 (35.4) - - 
 
679 (30.2) - - 
 
108 (33.6) - - 
 
35 (34.0) - - 
 
 
1 K+ < 3.3 mmol/l on day(s) of co-administration 
2 For clarithromycin if eGFR < 30 ml/min, for erythromycin if eGFR < 10 ml/min, for ciprofloxacin eGFR < 30 - 60 ml/min, for levofloxacin if eGFR < 20 - 50 ml/min  
 Table 3: ECG-monitoring in MQAB users at risk of TdP 
 
 Macrolides  Quinolones 
 Clarithromycin Erythromycin Azithromycin 
 Ciprofloxacin Levofloxacin Moxifloxacin 
 Hospitalizations Hospitalizations Hospitalizations 
 Hospitalizations Hospitalizations Hospitalizations 
 n % n % n % 
 n % n % n % 
              
Co-medication with at least one QT-prolonging drug1 259 (100) 48 (100) 65 (100)  632 (100) 180 (100) 52 (100) 
              
Current / pretreatment ECG available2 128 (49.4) 27 (56.3) 21 (32.3)  334 (52.8) 92 (51.1) 27 (51.9) 
  --> Thereof administration during episode(s) of hypokalemia3 37 (14.3) 7 (14.6) 6 (9.2)  79 (12.5) 21 (11.7) 10 (19.2) 
  --> Thereof with ICD-10 codes predisposing for TdP 70 (27.0) 9 (18.8) 11 (16.9)  483 (76.4) 40 (22.2) 12 (23.1) 
  --> Thereof with renal insufficiency requiring dose adaptation 19 (7.3) 1 (2.1) na na  123 (19.5) 14 (7.8) na na 
     --> Thereof with supratherapeutic dosing 1 (0.4) 0 (0.0) na na  7 (1.1) 3 (1.7) na na 
              
  --> Thereof abnormal / long QT4 9 (3.5) 2 (4.2) 2 (3.1)  36 (5.7) 6 (3.3) 0 (0.0) 
  --> Thereof non-drug-related abnormal / long QT5 5 (1.9) 1 (2.1) 0 (0.0)  20 (3.2) 4 (2.2) 0 (0.0) 
  --> Thereof causality not assessable (no ECG while exposed to DDI) 0 (0.0) 1 (2.1) 0 (0.0)  10 (1.6) 1 (0.6) 0 (0.0) 
  --> Thereof suspected drug related abnormal QT 4 (1.5) 0 (0.0) 2 (3.1)  6 (0.9) 1 (0.6) 0 (0.0) 
     --> Thereof WHO / CIOMS causality 'possible' for DDI regarding TdP 3 (1.2) 0 (0.0) 0 (0.0)  3 (0.5) 1 (0.6) 0 (0.0) 
              
No current / pretreatment ECG available2 131 (50.6) 21 (43.8) 44 (67.7)  298 (47.2) 88 (48.9) 25 48.1 
  --> Thereof with hypokalemia3 22 (8.5) 3 (6.3) 8 (12.3)  54 (8.5) 17 (9.4) 5 (9.6) 
  --> Thereof with ICD-10 codes predisposing for TdP 52 (20.1) 6 (12.5) 14 (21.5)  72 (11.4) 19 (10.6) 6 (11.5) 
  --> Thereof with renal insufficiency requiring dose adaptation 20 (7.7) 1 (2.1) na na  73 (11.6) 14 (7.8) na na 
     --> Thereof with supratherapeutic dosing 1 (0.4) 0 (0.0) na na  5 (0.8) 2 (1.1) na na 
 
1 After exclusion of patients without consent to access original medical records 
2 Current / pretreatment ECG available = ECG performed up to 7 days before co-administration of studied AB with drugs known to cause TdP 
3 K+ < 3.3 mmol/l on day(s) of co-administration 
4 Abnormal QTc = 450 ms for men / 460 ms for women; long QTc = > 500ms 
5 Presence of left bundle branch block / pacing pacemaker / use of amiodarone and (except AB) no other QT prolonging drugs 
  na = not applicable
Table 4: Adverse drug reactions associated with potential medication errors in MQAB users 
 
Case code Sex Age Antibiotic(s) Dose Antibiotic Additional QT prolonging drug(s) Dose additional  drug(s) Route of admin. AB Route of admin. QT drug 
Lung 
transplant QTc K
+ Mg2+ Heart rate CV diagnoses 
QT1 m 51 
clarithromycin, 
azithromycin, 
ciprofloxacin 
250 mg/3x per week domperidone, ondansetron 30 mg/d, 4 mg/d p.o. p.o. yes 491 3.3 0.98 90 - 
QT2 f 67 clarithromycin 500 mg/d domperidone 30 mg/d p.o. p.o. yes 486 4 0.87 68 multiple heart diseases 
QT3 m 47 clarithromycin 1000 mg/d ondansetron 8-16 mg/d i.v. i.v., p.o. no 484 4.3 - 55 - 
QT4 m 42 levofloxacin 500 mg/d ondansetron 24 mg/d i.v. i.v. no 481 4.3 0.85 81 - 
QT5 f 80 ciprofloxacin 500 mg/d citalopram 40 mg/d p.o. p.o. no 513 3.3 0.66 90 - 
QT6 m 78 ciprofloxacin 800 mg/d dipiperon, haloperidol (fix) 120 mg/d, 2 mg/d i.v. p.o. no 518 - 1 61 multiple heart diseases 
QT7 f 68 ciprofloxacin, azithromycin 250 mg/3x per week 
ciprofloxacin, domperidone, 
citalopram 500 mg/d, 30 mg/d, 10 mg/d p.o. p.o. yes 478   78 cardiomyopathy 
 
 
Supplementary Table 1: Study population including patient-days 
 
 Hospitalizations Patient-days 
 n (%) n (%) 
All analyzed MQAB users 3240 (100) 20721 (100) 
     
Sex     
Male 1913 (59.0) 12296 (59.3) 
Female 1327 (41.0) 8425 (40.7) 
     
Age distribution     
<18 14 (0.4) 69 (0.3) 
18-44 694 (21.4) 4106 (19.8) 
45-64 1195 (36.9) 8537 (41.2) 
65-84 1205 (37.2) 7272 (35.1) 
≥85 132 (4.1) 737 (3.6) 
     
Use of studied antibiotics     
Macrolides     
Clarithromycin 476 (14.7) 4238 (20.5) 
Erythromycin 184 (5.7) 901 (4.3) 
Azithromycin 113 (3.5) 725 (3.5) 
Quinolones     
Ciprofloxacin 2247 (69.4) 12989 (62.7) 
Levofloxacin 321 (9.9) 2389 (11.5) 
Moxifloxacin 103 (3.2) 857 (4.1) 
     
Units with highest use of MQAB     
Urology 677 (20.9) 2366 (11.4) 
Viszeral- and transplantation surgery 386 (11.9) 1895 (9.1) 
Internal medicine 381 (11.8) 1601 (7.7) 
Pneumology 271 (8.4) 3671 (17.7) 
Haematology 170 (5.2) 1551 (7.5) 
     
Most frequent primary ICD-10 diagnoses for hospitalizations with MQAB use     
Malignant neoplasms of lymphoid, hematopoietic and related tissue C81-C96 177 (5.5) - - 
Complications of surgical and medical care, not elsewhere classified T80-T88 151 (4.7) - - 
Other diseases of the urinary system N30-N39 142 (4.4) - - 
Influenza and pneumonia J09-J18 139 (4.3) - - 
Malignant neoplasms of digestive organs C15-C26 127 (3.9) - - 
 
 
